3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
68
Breast Neoplasms
58
Carcinoma, Non-Small-Cell Lung
36
Triple Negative Breast Neoplasms
28
Squamous Cell Carcinoma of Head and Neck
15
Neoplasms
11
Head and Neck Neoplasms
11
Lung Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Neoplasm Metastasis
7
Stomach Neoplasms
6
Melanoma
6
Adenocarcinoma
6
Esophageal Neoplasms
5
Cholangiocarcinoma
5
Advanced Pancreatic Cancer
5
Inflammatory Breast Neoplasms
4
Gallbladder Neoplasms
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Small Cell Lung Carcinoma
3
Recurrence
3
Pathologic Complete Response
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Carcinoma, Squamous Cell
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Interventions
seribantumab
2
Istiratumab
1
Gemcitabine
1
Docetaxel
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Fibromatosis, Gingival, 2
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02399137
2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2
Completed
88 enrolled